Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.59 |
| ▸ | CCR5 | P51681 | 1/20 | 0.59 |
| ▸ | CCR8 | P51685 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816965 | 0.79 | CCR1 (0.94) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| SCHEMBL14910966 | 0.77 | ASIC3 (0.53) | KDM4EALDH1A1GLAGAAPDE10A | |
| SCHEMBL181893 | 0.76 | CCR1 (1.00) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| SCHEMBL29397106 | 0.76 | CCR1 (1.00) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| SCHEMBL17742751 | 0.76 | PDE10A (0.50) | KDM4EALDH1A1GLAGAAPDE10A | |
| SCHEMBL337077 | 0.74 | — | — | |
| SCHEMBL6820852 | 0.74 | CCR1 (0.94) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| SCHEMBL6820765 | 0.74 | CCR1 (0.94) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9639295 | 0.74 | CCR1 (0.94) | CCR1CCR5CCR8KDM4EALDH1A1 | |
| SCHEMBL2258309 | 0.74 | CCR1 (0.94) | CCR1CCR5CCR8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | CCR1 202/4885CCR5 170/4885CCR8 361/4885 |
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | CCR1 368/4885CCR5 247/4885CCR8 523/4885 |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | CCR1 824/4885CCR5 1748/4885CCR8 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.